+Compare
DRIO
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
29.12M

DRIO DarioHealth Corp Forecast, Technical & Fundamental Analysis

a developer of technology to address the diabetic self-monitoring of blood glucose

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for DRIO with price predictions
07:00 PM EST Dec 07, 2023

DRIO in upward trend: price rose above 50-day moving average on December 08, 2023

DRIO moved above its 50-day moving average on December 08, 2023 date and that indicates a change from a downward trend to an upward trend. In of 42 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 29, 2023. You may want to consider a long position or call options on DRIO as a result. In of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for DRIO just turned positive on November 14, 2023. Looking at past instances where DRIO's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where DRIO advanced for three days, in of 256 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 129 cases where DRIO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DRIO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

DRIO broke above its upper Bollinger Band on December 01, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.428) is normal, around the industry mean (25.240). P/E Ratio (0.000) is within average values for comparable stocks, (79.553). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (6.249). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (1.255) is also within normal values, averaging (44.190).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. DRIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DRIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Abbott Laboratories (NASDAQ:ABT), Intuitive Surgical (NASDAQ:ISRG), Medtronic plc (NASDAQ:MDT), Boston Scientific Corp (NASDAQ:BSX), Edwards Lifesciences Corp (NASDAQ:EW), IQVIA Holdings (NASDAQ:IQV), Align Technology (NASDAQ:ALGN), Illumina (NASDAQ:ILMN), Exact Sciences Corp (NASDAQ:EXAS), Guardant Health (NASDAQ:GH).

Industry description

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

Market Cap

The average market capitalization across the Medical Specialties Industry is 6.41B. The market cap for tickers in the group ranges from 27 to 3.82T. MKYSF holds the highest valuation in this group at 3.82T. The lowest valued company is FOGCF at 27.

High and low price notable news

The average weekly price growth across all stocks in the Medical Specialties Industry was -0%. For the same Industry, the average monthly price growth was 10%, and the average quarterly price growth was -10%. SERA experienced the highest price growth at 118%, while IMMVF experienced the biggest fall at -95%.

Volume

The average weekly volume growth across all stocks in the Medical Specialties Industry was -15%. For the same stocks of the Industry, the average monthly volume growth was -48% and the average quarterly volume growth was -5%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 69
Price Growth Rating: 60
SMR Rating: 84
Profit Risk Rating: 87
Seasonality Score: 17 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I. Advisor
published Earnings

DRIO is expected to report earnings to fall 206.12% to -51 cents per share on March 19

DarioHealth Corp DRIO Stock Earnings Reports
Q4'23
Est.
$-0.52
Q3'23
Beat
by $1.01
Q2'23
Beat
by $1.08
Q1'23
Beat
by $0.08
Q4'22
Beat
by $0.05
The last earnings report on November 02 showed earnings per share of 49 cents, beating the estimate of -51 cents. With 107.21K shares outstanding, the current market capitalization sits at 29.12M.
A.I. Advisor
published General Information

General Information

a developer of technology to address the diabetic self-monitoring of blood glucose

Industry MedicalSpecialties

Profile
Fundamentals
Details
Industry
Medical Specialties
Address
18 W. 18th Street
Phone
+1 972 4770-6377
Employees
252
Web
https://www.mydario.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LPSN3.450.15
+4.55%
LivePerson
SNDR23.840.04
+0.17%
Schneider National
FRLN6.33N/A
N/A
Freeline Therapeutics Holdings plc
AEP79.64-0.56
-0.70%
American Electric Power Company
PTGX20.36-0.55
-2.63%
Protagonist Therapeutics

DRIO and

Correlation & Price change

A.I.dvisor tells us that DRIO and PACB have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DRIO and PACB's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DRIO
1D Price
Change %
DRIO100%
+3.89%
PACB - DRIO
31%
Poorly correlated
+2.51%
NVTA - DRIO
31%
Poorly correlated
-0.26%
ARAY - DRIO
30%
Poorly correlated
N/A
EXAS - DRIO
30%
Poorly correlated
-0.37%
BNGO - DRIO
29%
Poorly correlated
-3.29%
More

Groups containing DRIO

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DRIO
1D Price
Change %
DRIO100%
+3.89%
diabetes
(undefined stocks)
51%
Loosely correlated
+2.51%
Medical Specialties
(undefined stocks)
30%
Poorly correlated
+0.20%
Medical Specialties
(undefined stocks)
30%
Poorly correlated
+0.20%
middle east
(undefined stocks)
29%
Poorly correlated
+0.08%
medical research
(undefined stocks)
29%
Poorly correlated
+0.01%
More